COVID-19 Pulmonary / Cardiac

Updated Oct 9, 2021

8 APR 2020: Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 (NEJM)

9 APR 2020: Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia (Journal of Thrombosis)
“The incidence of VTE in patients with severe NCP is 25% (20/81), which may be related to poor prognosis.”

10 APR 2020: Incidence of thrombotic complications in critically ill ICU patients with COVID-19 (Thrombosis Research)
“The 31% incidence of thrombotic complications in ICU patients with COVID-19 infections is remarkably high.” 

10 APR 2020: Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans (medRxiv preprint)

12 MAY 2020: Cardiac Involvement in Patients Recovered From COVID-2019 Identified Using Magnetic Resonance Imaging (JACC Cardiovascular Imaging)
“Cardiac involvement was found in a proportion of patients recovered from COVID-19. CMR manifestation included myocardial edema, fibrosis, and impaired right ventricle function. Attention should be paid to the possible myocardial involvement in patients recovered from COVID-19 with cardiac symptoms.”

10 JUL 2020: Extrapulmonary manifestations of COVID-19 (Nature Medicine)
“Some examples of areas that require further attention include elucidation of the mechanism by which SARS-CoV-2 is disseminated to extrapulmonary tissues, understanding of the viral properties that may enhance extrapulmonary spread, the contribution of immunopathology and effect of anti-inflammatory therapies, anticipation of the long-term effects of multi-organ injury, the identification of factors that account for the variability in presentation and severity of illness, and the biological and social mechanisms that underlie disparities in outcomes.” 

5 MAY 2020: Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19 (Lancet)

14 MAY 2020: Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center, Clinicopathologic Case Series (Annals of Internal Medicine)
“COVID-19 predominantly involves the lungs, causing DAD and leading to acute respiratory insufficiency. Death may be caused by the thrombosis observed in segmental and subsegmental pulmonary arterial vessels despite the use of prophylactic anticoagulation. Studies are needed to further understand the thrombotic complications of COVID-19”
article on the paper: Autopsies Indicate Blood Clots Are Lethal in COVID-19 (TheScientist) 

15 MAY 2020: COVID-19 update: Covid-19-associated coagulopathy (Journal of Thrombosis)

25 JUN 2020: Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series (Lancet)
“In this series of seven COVID-19 autopsies, thrombosis was a prominent feature in multiple organs, in some cases despite full anticoagulation and regardless of timing of the disease course, suggesting that thrombosis plays a role very early in the disease process. The finding of megakaryocytes and platelet-rich thrombi in the lungs, heart and kidneys suggests a role in thrombosis.”

27 JUN 2020: Myocarditis in a 16-year-old boy positive for SARS-CoV-2 (Lancet)
“Paediatric patients reporting chest pain and other features suggestive of acute myocarditis—with or without respiratory symptoms—should, we believe, also be tested for SARS-CoV-2” 

3 JUL 2020: Complications from COVID-19 may depend on von Willebrand factor in the blood (EurekaAlert Press Release)
“As the researcher suggests, the replication of the virus stimulates the development of microdamage on vessel walls. In its response to this, the body releases von Willebrand factor into the blood, trying to ‘patch’ possible holes. As a result, the risk of thromboses increases. It is with this clotting that a significant part of the deaths from COVID-19 is associated.”

20 JUL 2020: Thrombosis in Hospitalized Patients With COVID-19 in a New York City Health System (JAMA Research Letter)
“Among 829 ICU patients, 29.4% had a thrombotic event (13.6% venous and 18.6% arterial). Among 2505 non-ICU patients, 11.5% had a thrombotic event (3.6% venous and 8.4% arterial).”

21 JUL 2020: Unexpected Features of Cardiac Pathology in COVID-19 Infection (Circulation Letter)
“We identify key gross and microscopic changes that challenge the notion that typical myocarditis is present in severe SARS-CoV-2 infection. We speculate on alternative mechanisms for cardiac injury that should be investigated to provide a better understanding of the cardiac manifestations of COVID-19.” 

 27 JUL 2020: Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (JAMA Cardiology)

12 AUG 2020: SARS-CoV-2 and Stroke Characteristics: A Report from the Multinational COVID-19 Stroke Study Group (medRxiv preprint)
“We observed a relatively high number of young, and asymptomatic SARS-CoV-2 infections among stroke patients. Traditional vascular risk factors were absent among a relatively large cohort of patients.”

25 AUG 2020: SARS-CoV-2 infection of human iPSC-derived cardiac cells predicts novel cytopathic features in hearts of COVID-19 patients (bioRxiv preprint)
“…these results suggest that a majority of patients could suffer long-term consequences of COVID-19 on cardiac function, and that even the mildest cases could cause permanent heart damage.”
Press Release (Gladstone Institutes)

21 APR 2021: SARS-CoV-2 and Stroke Characteristics (Stroke)
“We observed a considerably higher rate of large vessel occlusions, a much lower rate of small vessel occlusion and lacunar infarction, and a considerable number of young stroke when compared with the population studies before the pandemic. The rate of mechanical thrombectomy was significantly lower in countries with lower health expenditures.” … “Among 380 patients who had known interval onset of the SARS-CoV-2 and stroke, 144 (37.8%) were asymptomatic at the time of admission for SARS-CoV-2 infection.”

6 OCT 2021: One-year Risks and Burdens of Incident Cardiovascular Disease in COVID-19: Cardiovascular Manifestations of Long COVID (Nature preprint)
“our results provide evidence that risk and 1-year burden of cardiovascular disease in survivors of acute COVID-19 are substantial”